Market Place
Sourcing Support
Syros Announces Topline Data from SELECT-MDS-1 Trial in MDS
12 Nov 2024 //
BUSINESSWIRE
Rege Nephro Completes Series B Funding For Kidney Disease Trials
07 Oct 2024 //
PR NEWSWIRE
Syros To Host Webcast On MDS, Tamibarotene Opportunity In RARA Overexpression
13 Jun 2024 //
BUSINESSWIRE
Rege Nephro: Phase 2 Tamibarotene Trial In ADPKD Patient Enrollment
28 May 2024 //
PR NEWSWIRE
Syros Highlights 2024 Milestones to Deliver on the Value of Tamibarotene
08 Jan 2024 //
BUSINESSWIRE
Syros’ stock up after sharing early, mid-stage AML data
07 Dec 2023 //
FIERCE BIOTECH
Syros Announces Initial Data from Phase 2 Trial Evaluating Tamibarotene
06 Dec 2023 //
BUSINESSWIRE
Syros Receives Fast Track Designation from the FDA for Tamibarotene
26 Jan 2023 //
BUSINESSWIRE
Syros Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene
12 Dec 2022 //
BUSINESSWIRE
Syros Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
Syros Receives Positive Opinion on Orphan Drug Designation from the EMA
03 Aug 2022 //
BUSINESSWIRE
FDA orphan drug designation for treatment of rare blood cancer
03 Feb 2022 //
PHARMAFILE
Syros Receives FDA ODD for Tamibarotene for the Treatment of MDS
02 Feb 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.